tm
Seeing Is Believing
tm
Seeing Is Believing
GLUE is currently covered by 4 analysts with an average price target of $14.63. This is a potential upside of $6.27 (75%) from yesterday's end of day stock price of $8.36.
Monte Rosa Therapeutics's activity chart (see below) currently has 6 price targets and 15 ratings on display. The stock rating distribution of GLUE is 44.44% HOLD and 55.56% BUY.
Analysts average stock forecasts to be materialized ratio is 38.33% with an average time for these price targets to be met of 55.4 days.
Highest price target for GLUE is $17, Lowest price target is $16, average price target is $14.63.
Most recent stock forecast was given by DEREK ARCHILA from WELLS FARGO on 12-Aug-2024. First documented stock forecast 19-Jul-2021.
Currently out of the existing stock ratings of GLUE, 4 are a HOLD (44.44%), 5 are a BUY (55.56%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$17
$9.26 (119.64%)
$18
3 months 8 days ago
(12-Aug-2024)
0/3 (0%)
$13.02 (327.14%)
Buy
$16
$8.26 (106.72%)
$21
4 months 23 days ago
(28-Jun-2024)
1/4 (25%)
$12.26 (327.81%)
45
Buy
$10
$2.26 (29.20%)
$11
1 years 11 days ago
(09-Nov-2023)
2/3 (66.67%)
$6.7 (203.03%)
203
Hold
$11
$3.26 (42.12%)
$11
1 years 3 months 9 days ago
(11-Aug-2023)
0/4 (0%)
$4.31 (64.42%)
Hold
$20
$10.81 (117.63%)
3 years 1 months ago
(21-Oct-2021)
1/1 (100%)
$-4.92 (-19.74%)
29
What is GLUE (Monte Rosa Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on GLUE (Monte Rosa Therapeutics) with a proven track record?
Which analyst has the current lower performing score on GLUE (Monte Rosa Therapeutics) with a proven track record?
Which analyst has the most public recommendations on GLUE (Monte Rosa Therapeutics)?
Which analyst is the currently most bullish on GLUE (Monte Rosa Therapeutics)?
Which analyst is the currently most reserved on GLUE (Monte Rosa Therapeutics)?
